Stealthy Torque powers through with $21M raise

The biotech is working on I-O meds and has a growing team of biopharma vets

Flagship Pioneering’s quiet oncology upstart Torque Therapeutics has filed a $21 million raise as it lands in Kendall Square.

According to its SEC form picked up by the Boston Business Journal, the company has raised just shy of $21 million, with $35 million in total on the cards, and is being headed up by Merrimack’s founder and, until 2015, its CSO Ulrik Nielsen, Ph. D.

The biotech, based in Kendall Square, Cambridge, MA is working on so-called “Deep-Primed” immune cell therapeutics in cancer.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“We are using a technology platform to anchor powerful biotherapeutics—stimulatory cytokines, antibodies, and small molecules—directly to immune cells to direct and evoke immune cell responses, locally in the tumor microenvironment,” according to its website.

It has finished off preclinical studies with its first clinical candidate—Deep IL-15—which it says has shown “increased t-cell proliferation, engraftment, and tumor cell killing, including the potential to improve on pre-conditioning regimens.” The drug should enter the clinic in the first half of 2018.

It has a number of biopharma vets, including Becker Hewes, M.D., its CMO and most recently serving as an executive medical director at Novartis Institute for Biomedical Research, where he worked on I-O meds, among other cancer candidates.

Suggested Articles

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year.